Cardiovascular

Breaking News

Moderna and Chiesi establish collaboration for mRNA therapeutics

Moderna will receive $25m upfront and is eligible for more than $400m in development, regulatory, and commercial milestones

Vitamin K2 technology wins award for NattoPharma spin-off

Kaydence Pharma has received a start-up award at the BIO International convention

US FDA approves cardiovascular medicine from Baxter

The premixed format of eptifibatide to treat acute coronary syndrome is the first of its kind available in a flexible container

Study: Vitamin K2 deficiency increases cardiovascular stress

Improving vitamin K2 status could benefit arterial stiffening and calcification, reducing cardiovascular complications, new study finds

Crown Bioscience expands cardiovascular and metabolic disease research capability

The company offers new non-GLP services and translational rodent models at its expanded site in Louisiana

Domainex expands partnership with ICL to reduce heart muscle damage during heart attacks

The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays a key role in triggering cell death following a heart attack

Heart failure – serelaxin

Up to 10% of all those over 65 in the developed world have some form of heart failure and the long-term prognosis remains poor

Stem cell human heart tissue improves drug testing

Researchers at the Institute of Bioengineering and Nanotechnology and the Agency for Science, Technology and Research have engineered a 3D heart ti...

New research could help develop drugs to better address heart problems in diabetics

Researchers used a rat model to distinguish between the contributions of the two different beta-adrenoceptors

Heart failure – LCZ696

Novartis is developing a treatment that may help to relieve preserved ejection fraction heart failure

Positive CHMP opinion for Cardioxane in Europe

Clinigen, global pharmaceutical and services company, will receive CHMP from the European Commission, following complications on paediatric use and...

Heart failure – lixivaptan

Hyponatraemia is a problem in patients with heart failure as it causes cells to swell and affects blood pressure. Antagonising the vasopressin V2 r...

Non-alcoholic steatohepatitis market to increase more than fortyfold by 2026

Currently, the NASH market has no approved therapies and is dependent on off-label agents offering sub-optimal safety and efficacy outcomes

2011 nces focus on cancer therapies

The future of the pharma industry increasingly lies in drugs for diseases with smaller patient populations, and those targeted more precisely at sp...

In Brief

Axol Bioscience launch Human iPSC-derived Atrial Cardiomyocytes

Vasoprotective and antihypertensive effects of Vascazen formulation presented at ESC Congress 2014

6th Annual Diabetes Conference

Reports